GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease ( PL pro ), with an IC 50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC 50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C max of 549 ng/mL, a half-life T 1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse.
Products | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Virus Protease
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.